Patents by Inventor Knut T. Smerud

Knut T. Smerud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intranasal administration
    Patent number: 11730904
    Abstract: A delivery device for and method of modulating a condition relating to social cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: August 22, 2023
    Assignee: OptiNose, Inc.
    Inventors: Per Gisle Djupesland, Ramy A. Mahmoud, Ole A Andreassen, Lars T. Westlye, Daniel S. Quintana, Knut T. Smerud, Colin David Sheldrake
  • INTRANASAL ADMINISTRATION
    Publication number: 20210322690
    Abstract: A delivery device for and method of modulating a condition relating to social cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 21, 2021
    Inventors: Per Gisle Djupesland, Ramy A. Mahmoud, Ole A. Andreassen, Lars T. Westlye, Daniel S. Quintana, Knut T. Smerud, Colin David Sheldrake
  • Intranasal administration
    Patent number: 11052204
    Abstract: A delivery device for and method of modulating a condition relating to sodal cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 6, 2021
    Assignee: OptiNose AS
    Inventors: Per Gisle Djupesland, Ramy A. Mahmoud, Ole A Andreassen, Lars T. Westlye, Daniel S. Quintana, Knut T. Smerud, Colin David Sheldrake
  • Intranasal Administration
    Publication number: 20160310683
    Abstract: A delivery device for and method of modulating a condition relating to sodal cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.
    Type: Application
    Filed: November 19, 2015
    Publication date: October 27, 2016
    Inventors: Per Gisle Djupesland, Ramy A. Mahmoud, Ole A Andreassen, Lars T. Westlye, Daniel S. Quintana, Knut T. Smerud, Colin David Sheldrake